Withdrawal of rofecoxib - a wake up call for drug safety.
dc.contributor.author | Mishra, P | en_US |
dc.contributor.author | Palaian, S | en_US |
dc.date.accessioned | 2009-05-28T04:06:43Z | |
dc.date.available | 2009-05-28T04:06:43Z | |
dc.date.issued | 2004-10-03 | en_US |
dc.description | Kathmandu University Medical Journal. | en_US |
dc.description.affiliation | Dept. of Pharmacology, Manipal College of Medical Sciences Pokhara, Nepal. | en_US |
dc.identifier.citation | Mishra P, Palaian S. Withdrawal of rofecoxib - a wake up call for drug safety. Kathmandu University Medical Journal. 2004 Oct-Dec; 2(4): 360 | en_US |
dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/46436 | |
dc.language.iso | eng | en_US |
dc.source.uri | https://www.kumj.com.np | en_US |
dc.source.uri | https://kumj.com.np/ftp/issue/8/360-360.pdf | en_US |
dc.subject.mesh | Cyclooxygenase 2 Inhibitors --adverse effects | en_US |
dc.subject.mesh | Drug Approval | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Lactones --adverse effects | en_US |
dc.subject.mesh | Nepal | en_US |
dc.subject.mesh | Safety | en_US |
dc.subject.mesh | Sulfones --adverse effects | en_US |
dc.subject.mesh | United States | en_US |
dc.subject.mesh | United States Food and Drug Administration | en_US |
dc.title | Withdrawal of rofecoxib - a wake up call for drug safety. | en_US |
dc.type | Journal Article | en_US |